Active substanceDiosminDiosmin
Similar drugsTo uncover
  • Vasoket®
    pills inwards 
    Stragen Farma S.A.     Switzerland
  • Venolek®
    pills inwards 
    Bakter, OOO     Russia
  • Diosmin
    pills inwards 
    ATOLL, LLC     Russia
  • Diosmin
    pills inwards 
    VERTEKS, AO     Russia
  • Flebodia 600
    pills inwards 
  • Phlebofa
    pills inwards 
    ATOLL, LLC     Russia
  • Dosage form: & nbsppills
    Composition:

    for 1 tablet:

    Active substance: diosmin in terms of anhydrous substance - 600 mg;

    Excipients: gelatin - 50.0 mg, sodium carboxymethyl starch - 40.0 mg, magnesium stearate - 10.0 mg, microcrystalline cellulose - up to 1000 mg.

    Description:

    Oblong biconvex tablets with a risk on one side, from a greyish-brown to a greyish-yellow color, blotches of a lighter and darker shade are allowed.

    Pharmacotherapeutic group:Angioprotective agent
    ATX: & nbsp

    C.05.C.A.03   Diosmin

    Pharmacodynamics:

    Diosmin is a derivative of benzopyron. Refers to the group of bioflavonoids, has phlebotonizing and venoprotective action, reduces the permeability of the vascular wall. Reduces the extensibility and increases the tone of the veins, reduces venous congestion in the lower limbs. The venotonic effect of diosmin is dose-dependent. The mechanism of the venotonic action of the diosmin is not fully understood.It is assumed that the drug inhibits the activity of catechol-O-methyltransferase (an enzyme that degrades norepinephrine, which increases the tone of the veins). This hypothesis was confirmed in the course of experimental studies (under the conditions "ex vivo" diosmin intensified the vasoconstrictive effect of epinephrine, norepinephrine and serotonin on isolated fragments of superficial veins of the forearm and a large human saphenous vein. It was also shown that diosmin reduces the content of serum enzymes responsible for the metabolism of mucopolysaccharides in the venous wall.

    In clinical trials diosmin reduced the capacity of the venous bed and the volume of venous congestion (according to plethysmography), reduced the average pressure in the deep and superficial veins of the legs (according to ultrasound Doppler ultrasound) and increased systolic and diastolic arterial pressure in patients with postoperative orthostatic hypotension.

    Diosmin improves lymphatic drainage, increases the tone and frequency of lymphatic capillary contraction, increases their functional density, and reduces lymphatic pressure.

    Diosmin improves microcirculation. In experimental studies diosmin increased the resistance of capillaries (dose-dependent effect) and reduced their permeability in rats and guinea pigs with vitamin P deficiency, and also reduced capillary permeability induced by chloroform, histamine and hyaluronidase.

    Diosmin reduces the adhesion of leukocytes to the venous wall and their migration to parainous tissues, improves diffusion of oxygen and perfusion in the skin tissue. In experimental studies diosmin had an anti-inflammatory effect, blocking the production of free radicals, the synthesis of prostaglandins and thromboxane.

    Pharmacokinetics:

    Diosmin is rapidly absorbed from the gastrointestinal tract. It is detected in the blood plasma 2 hours after ingestion. The bioavailability of the drug after oral administration is approximately 40-57,9%. Part of the drug is metabolized by bacteria cecum to form hippuric and benzoic acids.

    The maximum concentration in the blood plasma is reached after 5 hours after administration. The drug accumulates in all layers of the wall of the hollow veins and subcutaneous veins of the lower limbs, to a lesser extent - in the kidneys, liver and lungs and other tissues. The volume of distribution of the drug is 62.1 liters.The maximum selective accumulation of diosmin and / or its metabolites in the wall of venous vessels is noted 9 hours after administration and is maintained for 96 hours.

    Diosmin is rapidly metabolized in the liver. The main metabolite is hydroxyphenylpropionic acid. Metabolites of diosmina are excreted mainly by kidneys in the form of conjugates with glucuronic acid. 79% of the received diosmina is excreted kidneys, 11% - intestines, 2.4% - with bile. Enterohepatic circulation of the drug is noted. After taking a radioactive isotope labeled diosmin, approximately 86% of the drug is excreted by the kidneys and intestines within 48 hours.

    Indications:

    • Varicose veins of the lower extremities (elimination of symptoms);
    • Chronic lymphovenous insufficiency of the lower extremities (elimination of symptoms);
    • Acute hemorrhoids (in complex therapy to relieve symptoms);
    • Disturbances of microcirculation (for example, with idiopathic edema).

    Contraindications:

    • Hypersensitivity to the components of the drug;
    • Children under 18 years of age (experience of use is limited);
    • Pregnancy (I trimester) and lactation period (experience of use is limited).

    Pregnancy and lactation:

    Experience with the drug in pregnant women is limited. There were no reports of any adverse reactions with the use of diosmin in pregnant women in clinical practice. In experimental studies, there was no teratogenic effect of diosmine on the course of pregnancy, embryo-fetal and postnatal development. However, for safety reasons, it is not recommended to use the drug in the first trimester of pregnancy. During the II and III trimester of pregnancy, it is recommended to use the drug with caution.

    During breastfeeding, taking the drug is not recommended. there is no data on the penetration of the drug into breast milk.
    Dosing and Administration:

    The drug is intended for oral administration.

    With varicose veins of the lower extremities and chronic lymphovenous insufficiency

    The drug is prescribed 1 tablet per day in the morning on an empty stomach. The duration of therapy is usually 2 months. In severe forms of chronic lymphovenous insufficiency (swelling, pain, cramps, etc.) treatment can be longer (the total duration of continuous therapy should not exceed three to four months).The courses of treatment with Phlebofa are repeated after 2-3 months.

    For treatment of chronic lymphovenous insufficiency during the II and III trimester of pregnancy, the drug is prescribed 1 tablet 1 time per day. It is necessary to stop taking the drug 2-3 weeks before the birth.

    With an exacerbation of hemorrhoids

    The drug is prescribed for 2-3 tablets per day during meals for 7 days. Further, if necessary, you can continue taking the drug 1 tablet 1 time per day for 1-2 months.

    With violations of microcirculation

    The drug is prescribed 1 tablet per day in the morning on an empty stomach. The duration of therapy is usually 1-2 months.

    If you miss one or more of the medications, you must continue to use the drug in the usual mode and in a regular dose.

    Side effects:

    The frequency of side effects is determined according to the WHO classification of unwanted drug reactions by the frequency of occurrence: very often more than 1/10, often more than 1/100 and less than 1/10, infrequently more than 1/1000 and less than 1/100, more than 1/10000 and less than 1/1000, very rarely - less than 1/10000, including isolated cases.

    From the gastrointestinal tract: often - nausea, vomiting, diarrhea, dyspeptic disorders, heartburn, constipation.

    From the central nervous system: rarely - headache, malaise, dizziness.

    From the skin and subcutaneous fat: rarely - rashes, itching;

    Allergic reactions: rarely - hives.

    Overdose:

    Cases of overdose are not described. Given the wide therapeutic range of diosmosis, the risk of intoxication with an overdose is insignificant. The specific antidote is unknown.

    Interaction:

    Clinically significant interactions of diosmin with others are not described.

    Special instructions:

    Treatment of acute hemorrhoids is carried out in conjunction with other drugs. In the absence of a rapid clinical effect, it is recommended to consult a proctologist, if necessary, to conduct an additional examination and adjust the therapy.

    The experience of using diosmin in children younger than 18 years is not enough.

    Effect on the ability to drive transp. cf. and fur:

    The drug does not affect the ability to drive vehicles and mechanisms.

    Form release / dosage:

    Tablets 600 mg.

    Packaging:

    For 10 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

    On 10, 20, 30, 40, 50, 60 or 100 tablets in a can of polymer for medicines. One jar or 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 contour mesh packages together with the instruction for use are placed in a cardboard package.

    It is allowed to bundle 2 or 3 cardboard packages (packs) into a group package (shipping container) made of cardboard.

    Storage conditions:In the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:

    3 years. Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-002517
    Date of registration:01.07.2014 / 28.12.2015
    The owner of the registration certificate:ATOLL, LLC ATOLL, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp14.01.16
    Illustrated instructions
      Instructions
      Up